Cargando…

Dalbavancin as an option for treatment of S. aureus bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial

BACKGROUND: Staphylococcus aureus bacteremia is a life-threatening infection and leading cause of infective endocarditis, with mortality rates of 15–50%. Treatment typically requires prolonged administration of parenteral therapy, itself associated with high costs and potential catheter-associated c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Turner, Nicholas A., Zaharoff, Smitha, King, Heather, Evans, Scott, Hamasaki, Toshimitsu, Lodise, Thomas, Ghazaryan, Varduhi, Beresnev, Tatiana, Riccobene, Todd, Patel, Rinal, Doernberg, Sarah B., Rappo, Urania, Fowler, Vance G., Holland, Thomas L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9109297/ https://www.ncbi.nlm.nih.gov/pubmed/35578360 http://dx.doi.org/10.1186/s13063-022-06370-1

Ejemplares similares

233. Safety of Ceftazidime-Avibactam (CZA) in Combination with Aztreonam (ATM) in a Phase I, Open-Label Study in Healthy Adult Subjects (COMBINE)
por: Lodise, Thomas, et al.
Publicado: (2022)

Outcomes in Patients with Staphylococcus aureus Bacteremia Treated with Dalbavancin in Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

1660. Dalbavancin Utilization Registry Investigating Value and Effectiveness (DRIVE): Outcomes Report on Real-World Use
por: Jones, Bruce M, et al.
Publicado: (2022)

Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection in Patients With Obesity or Diabetes: A Subgroup Analysis of Pooled Phase 3 Clinical Trials
por: Riccobene, Todd, et al.
Publicado: (2023)

1000. Antimicrobial Susceptibility of Gram-Positive Bacteria Isolated From Patients Hospitalized With Bacteremia in United States and European Medical Centers: Results From the International Dalbavancin Evaluation of Activity (IDEA) Program
por: Sader, Helio S, et al.
Publicado: (2018)

279. Dalbavancin for Bloodstream Infections and Endocarditis: Real-World Outcomes From the DRIVE Registry
por: Gonzalez, Pedro, et al.
Publicado: (2020)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI) in the Obese Population
por: Georgiades, Benjamin, et al.
Publicado: (2017)

Treatment of acute bacterial skin and skin structure infection with single-dose dalbavancin in persons who inject drugs
por: Gonzalez, Pedro Luis, et al.
Publicado: (2018)

The Safety and Efficacy of Dalbavancin and Active Comparator in Pediatric Patients With Acute Bacterial Skin and Skin Structure Infections
por: Giorgobiani, Manana, et al.
Publicado: (2022)

Efficacy and Safety of Dalbavancin for the Treatment of Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Patients with Diabetes Mellitus
por: Nowak, Michael, et al.
Publicado: (2017)

Epithelial Lining Fluid and Plasma Concentrations of Dalbavancin in Healthy Adults after a Single 1,500-Milligram Infusion
por: Rappo, Urania, et al.
Publicado: (2019)

Dalbavancin for Staphylococcus aureus Bacteremia: Are We There Yet?
por: Mahatanan, Rattanaporn, et al.
Publicado: (2023)

Dalbavancin for the Treatment of Osteomyelitis in Adult Patients: A Randomized Clinical Trial of Efficacy and Safety
por: Rappo, Urania, et al.
Publicado: (2018)

Dalbavancin in the Treatment of Bacteremia and Endocarditis in People with Barriers to Standard Care
por: Ajaka, Leama, et al.
Publicado: (2020)

Safety of Dalbavancin in the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Nephrotoxicity Rates Compared with Vancomycin: A Post Hoc Analysis of Three Clinical Trials
por: Gonzalez, Pedro L., et al.
Publicado: (2021)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

Dalbavancin
por: Barberán, José, et al.
Publicado: (2021)

2255. The Use of Dalbavancin for Staphylococcus aureus Bacteremia in Persons Who Inject Drugs (PWID)
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

971. Pharmacokinetic Estimation Analysis of Multi-Dose Regimens of Dalbavancin for Treatment of Osteomyelitis or Bacteremia
por: Volk, Cecilia, et al.
Publicado: (2023)

1829. Dalbavancin versus standard of care as directed therapy for Staphylococcus aureus bacteremia in patients unable to receive OPAT
por: Frazier, J, et al.
Publicado: (2022)

1321. Population Pharmacokinetic (PK) and Pharmacokinetic/Pharmacodynamic (PK/PD) Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J, et al.
Publicado: (2020)

Evolution of Antibiotic Tolerance During Oxacillin, Daptomycin and Dalbavancin Therapy Results in Breakthrough Staphylococcus aureus Bacteremias
por: Berti, Andrew, et al.
Publicado: (2017)

Associations Between Vancomycin Exposure and Acute Kidney Injury Within the Recommended Area Under the Curve Therapeutic Exposure Range Among Patients With Methicillin-Resistant Staphylococcus aureus Bloodstream Infections
por: Lodise, Thomas P, et al.
Publicado: (2022)

223. Development and Analysis of a Novel DOOR Endpoint for Complicated Intra-abdominal Infections (cIAI) Using 10 Registrational Trials for Antibacterial Drugs
por: Kinamon, Tori, et al.
Publicado: (2022)

A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection
por: Howard-Anderson, Jessica, et al.
Publicado: (2022)

Ceftobiprole versus daptomycin in Staphylococcus aureus bacteremia: a novel protocol for a double-blind, Phase III trial
por: Hamed, Kamal, et al.
Publicado: (2020)

Dalbavancin: a novel antimicrobial
por: Chen, A Y, et al.
Publicado: (2007)

Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source—a series of four cases
por: Hitzenbichler, Florian, et al.
Publicado: (2020)

217. Antimicrobial Activity of Dalbavancin against Gram-Positive Bacteria Isolated from Patients Hospitalized with Bacteremia in United States and European Medical Centers: Results from the International Dalbavancin Evaluation of Activity (IDEA) Program (2018-202)
por: Sader, Helio S, et al.
Publicado: (2021)

1592. Antimicrobial Activity of Ceftazidime-Avibactam and Comparator Agents Against Enterobacterales and Pseudomonas aeruginosa With Overexpression of AmpC β-Lactamase From Phase 3 Clinical Trials
por: Lin, Lynn-Yao, et al.
Publicado: (2020)

Comparative Analysis of Dalbavancin versus Other Antimicrobial Options for Gram-Positive Cocci Infections: Effectiveness, Hospital Stay and Mortality
por: de Pablo-Miró, Mar, et al.
Publicado: (2021)

267 Dalbavancin for the treatment of Streptococcal Skin Infections
por: Puttagunta, Sailaja, et al.
Publicado: (2014)

Successful Treatment of Diabetic Foot Osteomyelitis with Dalbavancin
por: Loupa, Chariclia V., et al.
Publicado: (2020)

Dalbavancin: novel candidate for COVID-19 treatment
por: Hoffmann, Markus, et al.
Publicado: (2021)

Evaluating the Use of Dalbavancin for Off-Label Indications
por: Taylor, Katherine, et al.
Publicado: (2022)

Global trends of dalbavancin: A bibliometric analysis
por: Monteagudo‐Martínez, Nuria, et al.
Publicado: (2022)

The Effect of Dalbavancin in Moderate to Severe Hidradenitis Suppurativa
por: Molinelli, Elisa, et al.
Publicado: (2022)

2902. Dalbavancin Use in Bone and Joint Infections
por: Sanikommu, Srivani, et al.
Publicado: (2023)

2764. Experience with dalbavancin in a pediatric hospital
por: Leon, Maria Deza, et al.
Publicado: (2023)

LB2302. Ceftobiprole Compared to Daptomycin With or Without Optional Aztreonam for the Treatment of Complicated Staphylococcus aureus (SAB): Results of a Phase 3, Randomized, Double-Blind Trial (ERADICATE)
por: Holland, Thomas L, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_40r2omfisep8a4o1iaqm6vmo59